AstraZeneca Announces $1.175 Billion Investment in New Drug Manufacturing Facilities in Qingdao and Wuxi, China

Special Topic: 2024 Annual Meeting of the China Development Forum

Securities Times eCompany News: According to a CGTN Global Business Weibo post, AstraZeneca CEO Pascal Soriot, in an interview, stated that the company has invested $700 million (approximately RMB 5.06 billion) and $475 million respectively in building new pharmaceutical factories in Qingdao and Wuxi, China. He expressed strong confidence in the company’s long-term development in China.

Editor: Li Siyang